bioAffinity Technologies, Inc. (BIAFW)
NASDAQ: BIAFW · Real-Time Price · USD
0.600
+0.055 (10.01%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung.
It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Maria Zannes |
Contact Details
Address: 22211 West Interstate 10, Suite 1206 San Antonio, Texas 78257 United States | |
| Phone | 210 698 5334 |
| Website | bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAFW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W117 |
| ISIN Number | US09076W1172 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes J.D. | Founder, President, Chief Executive Officer and Director |
| Steven Girgenti | Founder and Executive Chairman of the Board |
| J. Michael Edwards CPA, M.B.A. | Chief Financial Officer and Principal Accounting Officer |
| Xavier T. Reveles M.S. | Chief Operating Officer |
| Dr. William Bauta Ph.D. | Chief Science Officer |
| Timothy P. Zannes J.D. | Executive Vice President, Secretary and General Counsel |
| Julie Anne Overton | Director of Communications |
| Dallas J. Coleman | Vice President of sales |